A meta-analysis of soluble suppression of tumorigenicity 2 (sST2) and clinical outcomes in pulmonary hypertension

J Geriatr Cardiol. 2017 Dec;14(12):766-771. doi: 10.11909/j.issn.1671-5411.2017.12.007.

King Sum Luk^{1

2}, Christina Ip^{1

2}, Meng-Qi Gong³, Sunny Hei Wong^{1

2}, William Kk Wu^{2

4}, Mei Dong⁵, Guang-Ping Li³, Ka Pang Chan¹, Yi-Mei Du⁶, Tong Liu³, Martin Cs Wong^{7

8}, David Shu Cheong Hui¹, Gary Tse^{1

2}; International Health Informatics Study (IHIS) Network

¹ Department of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China.
² Li Ka Shing Institute of Health Sciences, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China.
³ Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.
⁴ Department of Anaesthesia and Intensive Care, State Key Laboratory of Digestive Disease, LKS Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
⁵ The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Qilu Hospital, Shandong University, Jinan, China.
⁶ Research Center of Ion Channelopathy, Institute of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
⁷ JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.
⁸ State Key Laboratory of Digestive Disease, LKS Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, China.

No abstract available

Keywords: Mortality; Poor outcomes; Pulmonary hypertension; SST2; Soluble suppression of tumorigenicity 2.